
John Fesko/LinkedIn
Aug 19, 2025, 12:28
John Fesko Reflects on IMvigor011 Bladder Cancer Trial
John Fesko, President and Chief Business Officer at Natera, shared a post on LinkedIn:
“15 years ago, seeing someone I love decline chemo for muscle-invasive bladder cancer sparked my interest in circulating tumor DNA. Today, Genentech’s Phase 3 Atezolizumab results, as Professor Thomas Powles notes, open the door to ‘a new treatment paradigm’ for patients who are ‘positive for recurrence on a molecular level but have no evidence of disease on imaging.'”
Read More about IMvigor011 Trial on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 19, 2025, 12:28
Aug 19, 2025, 12:18
Aug 19, 2025, 12:03
Aug 19, 2025, 11:37
Aug 19, 2025, 11:21
Aug 19, 2025, 11:08
Aug 19, 2025, 11:00
Aug 19, 2025, 10:53